Insulet Corporation (PODD) - Total Assets
Based on the latest financial reports, Insulet Corporation (PODD) holds total assets worth $2.99 Billion USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check Insulet Corporation cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Insulet Corporation - Total Assets Trend (2002–2025)
This chart illustrates how Insulet Corporation's total assets have evolved over time, based on quarterly financial data. Explore investment intensity of Insulet Corporation to see how much of total assets are deployed in long-term investments.
Insulet Corporation - Asset Composition Analysis
Current Asset Composition (December 2025)
Insulet Corporation's total assets of $2.99 Billion consist of 59.2% current assets and 40.8% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 22.5% |
| Accounts Receivable | $516.90 Million | 16.2% |
| Inventory | $452.60 Million | 14.2% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $117.10 Million | 3.7% |
| Goodwill | $51.60 Million | 1.6% |
Asset Composition Trend (2002–2025)
This chart illustrates how Insulet Corporation's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see market cap of Insulet Corporation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Insulet Corporation's current assets represent 59.2% of total assets in 2025, a decrease from 96.9% in 2002.
- Cash Position: Cash and equivalents constituted 22.5% of total assets in 2025, down from 96.9% in 2002.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 4.0% of total assets, an increase from 0.0% in 2002.
- Asset Diversification: The largest asset category is accounts receivable at 16.2% of total assets.
Insulet Corporation Competitors by Total Assets
Key competitors of Insulet Corporation based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
COCHLEAR LTD ADR 1/2/O.N.
F:OC50
|
Germany | €2.83 Billion |
|
Jiangsu Yuyue Medical Equipment & Supply Co Ltd
SHE:002223
|
China | CN¥16.89 Billion |
|
Novocure Ltd
NASDAQ:NVCR
|
USA | $787.93 Million |
|
Shanghai MicroPort EV MedTech Co. Ltd. A
SHG:688351
|
China | CN¥2.00 Billion |
|
Jafron Biomedical Co Ltd
SHE:300529
|
China | CN¥5.52 Billion |
|
Anteris Technologies Global Corp
AU:AVR
|
Australia | AU$19.07 Million |
|
Beijing Chunlizhengda Medical Instruments Co Ltd
SHG:688236
|
China | CN¥3.54 Billion |
|
Tellgen Corp
SHE:300642
|
China | CN¥2.01 Billion |
Insulet Corporation - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.49 | 4.43 | 5.87 |
| Quick Ratio | 1.81 | 3.59 | 4.95 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $1.02 Billion | $1.79 Billion | $1.04 Billion |
Insulet Corporation - Advanced Valuation Insights
This section examines the relationship between Insulet Corporation's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 8.04 |
| Latest Market Cap to Assets Ratio | 3.21 |
| Asset Growth Rate (YoY) | 3.3% |
| Total Assets | $3.19 Billion |
| Market Capitalization | $10.23 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Insulet Corporation's assets at a significant premium (3.21x), suggesting investors see substantial growth potential or unique competitive advantages.
Positive Asset Growth: Insulet Corporation's assets grew by 3.3% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Insulet Corporation (2002–2025)
The table below shows the annual total assets of Insulet Corporation from 2002 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $3.19 Billion | +3.33% |
| 2024-12-31 | $3.09 Billion | +19.30% |
| 2023-12-31 | $2.59 Billion | +14.97% |
| 2022-12-31 | $2.25 Billion | +9.87% |
| 2021-12-31 | $2.05 Billion | +9.39% |
| 2020-12-31 | $1.87 Billion | +63.87% |
| 2019-12-31 | $1.14 Billion | +23.06% |
| 2018-12-31 | $928.74 Million | +13.71% |
| 2017-12-31 | $816.74 Million | +78.86% |
| 2016-12-31 | $456.65 Million | +65.98% |
| 2015-12-31 | $275.13 Million | -8.95% |
| 2014-12-31 | $302.16 Million | +4.93% |
| 2013-12-31 | $287.95 Million | +45.39% |
| 2012-12-31 | $198.06 Million | -5.50% |
| 2011-12-31 | $209.58 Million | +34.15% |
| 2010-12-31 | $156.23 Million | -8.98% |
| 2009-12-31 | $171.65 Million | +57.15% |
| 2008-12-31 | $109.23 Million | -16.45% |
| 2007-12-31 | $130.74 Million | +128.81% |
| 2006-12-31 | $57.14 Million | +240.28% |
| 2005-12-31 | $16.79 Million | -38.08% |
| 2004-12-31 | $27.12 Million | +447.01% |
| 2003-12-31 | $4.96 Million | -71.69% |
| 2002-12-31 | $17.51 Million | -- |
About Insulet Corporation
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain… Read more